Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNC-301 is an early-stage microbiome-based therapeutic candidate developed by CNcure for the treatment of colon cancer. Utilizing CNcure's microbiome platform, CNC-301 is designed as a live biotherapeutic product (LBP) that modulates the gut microbiota to exert anti-tumor effects. The program is currently in the hit-to-lead phase, focusing on identifying and optimizing bacterial strains that can effectively alter the tumor microenvironment or stimulate systemic anti-cancer immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CNC-301.